The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Mon, 04th May 2020 14:35

(Alliance News) - Open Orphan PLC on Monday announced that Chief Executive Trevor Phillips will be standing down and said it has signed a new contract with a US biotechnology.

Shares in the pharmaceutical services firm were up 10% at 9.90 pence in London in afternoon trading.

Philips will stay in his role until June end but has departed the board with immediate effects. He joined hVIVO at the end of 2018 and led hVIVO's merger with Open Orphan. Executive Chair Cathal Friel will lead Open Orphan.

The new contract is for Open Orphan to provide a human challenge study in respiratory syncytial virus, a highly contagious viral disease and among the most common causes of pneumonia and bronchiolitis. Challenge studies purposefully expose healthy volunteers to an infectious disease.

The biotechnology company's name was not disclosed, though Open Orphan expects to receive around GBP3.5 million of revenue in 2020 from the study.

Open Orphan acquired Venn Life Sciences Holdings PLC in January, the same month its completed its merger with hVIVO PLC. The study will use the clinical research organisation services of hVIVO and Venn and will take place at hVIVO's London-based quarantine unit in the third quarter of 2020.

Friel said: "Firstly, I would like to thank Trevor for his help merging Open Orphan and hVIVO. Trevor had previously successfully right sized and focused hVIVO and our refreshed management team is now focused on delivering growth at a very exciting time for the company.

"The signing of this new GBP3.5 million contract with a US biotechnology company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts. Open Orphan will be utilising its complementary in-house [clinical research organisation] services of hVIVO and Venn to deliver this contract. This contract demonstrates the Open Orphan and hVivo group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reduce costs."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
11 May 2020 12:03

UK TRADING UPDATE SUMMARY: Blencowe And BlueRock Recommence Operations

UK TRADING UPDATE SUMMARY: Blencowe And BlueRock Recommence Operations

Read more
11 May 2020 09:06

Open Orphan inks contract with Quotient on Covid-19 antibody testing

(Sharecast News) - Pharmaceutical services company Open Orphan's hVIVO subsidiary has entered into an exclusive contract with Quotient to support Covid-19 antibody testing in the UK.

Read more
4 May 2020 16:21

Open Orphan signs ?3.5m deal with US biotech firm

(Sharecast News) - Pharmaceutical services company Open Orphan announced the signing of a new contract with an unnamed US biotechnology company on Monday, for the provision of a respiratory syncytial virus (RSV) human challenge study.

Read more
23 Apr 2020 15:40

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

Read more
23 Apr 2020 10:21

Open Orphan begins testing of Covid-19 anti-viral treatment

(Sharecast News) - Pharmaceutical services company Open Orphan said it had started testing an anti-viral drug to treat Covid-19 on behalf of its client Nearmedic International.

Read more
10 Mar 2020 14:48

Open Orphan Notes Publication Of FLU-v Vaccine Study In Journal

Open Orphan Notes Publication Of FLU-v Vaccine Study In Journal

Read more
9 Mar 2020 14:17

Open Orphan Starts On Coronavirus Challenge Study Model

Open Orphan Starts On Coronavirus Challenge Study Model

Read more
6 Mar 2020 15:23

Open Orphan agrees study with European biotech firm

(Sharecast News) - Orphan drugs-focussed pharmaceutical company Open Orphan announced the signing of a new contract with an unnamed European biotechnology firm for the provision of an RSV human challenge study.

Read more
6 Mar 2020 11:57

Open Orphan Inks New Virus Study Contract With Potential Follow-On

Open Orphan Inks New Virus Study Contract With Potential Follow-On

Read more
27 Feb 2020 17:56

EXECUTIVE CHANGE SUMMARY: Burford Capital Adds Independent Directors

EXECUTIVE CHANGE SUMMARY: Burford Capital Adds Independent Directors

Read more
13 Feb 2020 14:45

Open Orphan Appoints Interim CFO Leo Toole To Permanent Role

Open Orphan Appoints Interim CFO Leo Toole To Permanent Role

Read more
31 Jan 2020 15:39

Open Orphan raising at least ?5m for merger with hVIVO

(Sharecast News) - Pharmaceutical services company Open Orphan announced a fundraising to raise a minimum of £5m before expenses via a conditional placing of new ordinary shares on Friday, at a price of 6.1p each, to institutional and other investors.

Read more
31 Jan 2020 12:39

Open Orphan Raises GBP5.3 Million To Fund hVIVO Synergy Programme

Open Orphan Raises GBP5.3 Million To Fund hVIVO Synergy Programme

Read more
23 Jan 2020 18:32

Open Orphan In Talks With Investors Regarding GBP5 Million Placing

Open Orphan In Talks With Investors Regarding GBP5 Million Placing

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.